Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

The purpose of this research study is to investigate how and why the loss of muscle mass occurs with aging. Tissue collected from young subjects will be compared to previously collected tissue from elderly subjects, as well as previously collected data on muscle function/mass to further investigate cellular and molecular pathways that have recently been shown to be important for the aging process in muscle. The Principal Investigator (PI) and the study team will look for specific proteins (called biomarkers) that can be present in the muscle tissue in various amounts in different individuals. This study will increase the investigators understanding of the processes of muscle atrophy (loss of mass) and functional loss at older age and will help to find new treatments and interventions aimed at improving the quality of life and independence of America's rapidly expanding elderly population.

Study Overview

• Status: Completed
• Conditions: Sarcopenia

Detailed Description

For this project, we will continue to gain mechanistic insight into age-related muscle loss and to maximize the utility of the tissue we previously collected (Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal muscle apoptosis and physical performance; Oxidative RNA/DNA damage and repair in aged human muscle (Developmental Study), IRB # 429-2005) and we will collect muscle tissue from additional young subjects. This project will specifically test whether inflammatory pathways and DNA repair mechanisms are altered and/or involved in the development of sarcopenia and the related decline in physical function observed in the elderly.

Aim 1. We will further determine the association of skeletal muscle mass and function with intramuscular mediators of inflammation. Focus will be on inflammatory proteins (e.g.,TNF, TNFR1, pIkBα, pIKKb, CCL2, ZIP14, ZnT2) and genes (e.g., IL-6, TNFa, IL11β, IL-8, CCL2, CCR2, NFkB p50, NFkB p65, ZIP14) and metals (e.g., copper, zinc, and iron). We hypothesize that the majority of these markers will be upregulated in muscle from older individuals when compared to young.

Aim 2. For the first time, we will determine the age related effect of DNA damage on pattern and dynamics of mRNA translation in human muscle tissue by genome wide analysis using "ribosome profiling." The recently developed deep-sequencing techniques of RNA-seq and "ribosome profiling" will be implemented on human muscle. This will allow us to explore on a genomic scale and at single-nucleotide resolution, the effect of age-related DNA damage on transcriptional fidelity and translational kinetics. Importantly, for the first time, these phenotype changes will be compared with genome mapping of DNA damage, a major factor driving mammalian aging. We hypothesize that older muscle has greater modification of translational patterns compared to young muscle.

Muscle tissue samples remaining following the completion of this research will be stored and used in the future to explore new avenues of research related to aging.

• Study Type: Observational
• Enrollment (Actual): 10

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32611
      • University of Florida

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Young (age 20-35 years; N =10)

Description

Inclusion Criteria:

• males and females aged 20-35.
• willing and able to give informed consent.

Exclusion Criteria:

• High physical activity level (i.e., the subject has spent greater than 300 minutes per week in the past 2 month performing structured physical activity, such as exercising at a gym and/or weight training)
• Active treatment for cancer or history of cancer in the past 3 years
• Congestive heart failure NYHA Class III or IV
• Previous stroke with upper and/or lower extremities involvement within the last 6 months
• Peripheral vascular disease Fontaine Class III/IV
• History of life-threatening cardiac arrhythmias, stroke, severe Parkinson's disease or severe neurological disorders likely to interfere with physical function
• Renal disease requiring dialysis
• Lung disease requiring steroids
• Lower extremity amputation
• Complicated diabetes
• Life-threatening illnesses with an estimated life expectancy less than 1 year
• Anticoagulant therapy (aspirin use is allowed, but participants will be asked to stop taking it 48 hours prior to muscle biopsy)
• Involved in active weight loss > 5 kg in prior 3 months
• Pregnancy (determined by a pregnancy test)
• Lidocaine allergy

Temporary exclusion criteria:

• Recent bacterial infection (< 2 weeks)
• Acute febrile illness in previous 2 months
• High blood pressure (i.e., BP ≥ 160/90 mm Hg) at the visit (subject will be referred to his/her physician and reevaluated after appropriated therapy being instituted)
• Taking aspirin within 48 hours preceding biopsy
• Performing exercise 48 hours prior to the biopsy.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Young; Young (20-35 years old)
Old; Older (70-99 years old)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor Necrosis Factor alpha (TNF-alpha)	Inflammation marker; measured in muscle biopsy specimens.	baseline
tumor-necrosis factor receptor-1 (TNFR1)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Phospho-Inhibitory Subunit Of NF-KBα (pIkBα)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Chemokine (C-C motif) ligand 2 (CCL2)	Inflammation marker; measured in muscle biopsy specimens.	baseline
zinc transporter (ZIP) 14	Inflammation marker; measured in muscle biopsy specimens.	baseline
Interleukin 6 (IL-6)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Interleukin (IL) 11β	Inflammation marker; measured in muscle biopsy specimens.	baseline
Interleukin 8 (IL-8)	Inflammation marker; measured in muscle biopsy specimens.	baseline
C-C chemokine receptor type 2 (CCR2)	Inflammation marker; measured in muscle biopsy specimens.	baseline
zinc transporter 14 (ZIP14)	Inflammation marker; measured in muscle biopsy specimens.	baseline
copper	metals; measured in muscle biopsy specimens.	baseline
zinc	metals; measured in muscle biopsy specimens.	baseline
iron	metals; measured in muscle biopsy specimens.	baseline
ribosome profiling	DNA damage on pattern and dynamics of mRNA translation in human muscle tissue; measured in muscle biopsy specimens.	baseline

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: National Institute on Aging (NIA)
• Investigators: Principal Investigator: Christiaan Leeuwenburgh, PhD, University of Florida

Publications and helpful links

Helpful Links

• University of Florida Claude D. Pepper Older Americans Independence Center (OAIC)

Study record dates

Study Major Dates

• Study Start: May 1, 2014
• Primary Completion (Actual): July 1, 2016
• Study Completion (Actual): July 1, 2016

Study Registration Dates

• First Submitted: April 14, 2014
• First Submitted That Met QC Criteria: April 15, 2014
• First Posted (Estimate): April 16, 2014

Study Record Updates

• Last Update Posted (Actual): April 5, 2018
• Last Update Submitted That Met QC Criteria: April 4, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Keywords: mitochondria; aging; inflammation; sarcopenia; skeletal muscle
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Inflammation; Sarcopenia; Myositis
• Other Study ID Numbers: 201300790-N; 2P30AG028740 (U.S. NIH Grant/Contract)